AGFA HealthCare
MORTSEL, BELGIUM / ACCESSWIRE / June 10, 2024 / AGFA HealthCare is thrilled to announce a significant new deal with Alliance Medical to implement an advanced cloud-based solution across all of Alliance Medical's UK sites. Powered by the AGFA HealthCare Enterprise Imaging Platform, this state-of-the-art approach supports Alliance Medical UK's Future Unified Diagnostic Information System (FUDIS) project. This project aims to streamline the entire patient pathway, establishing a robust and lasting partnership between AGFA HealthCare and Alliance Medical.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Deployment of the solution will begin later in 2024, with a phased implementation approach to ensure a smooth and efficient transition of all imaging services across 120 sites for all of Alliance Medical's UK community diagnostic centres (CDCs), static imaging sites for PET-CT, MRI, CT and other imaging modalities and its extensive fleet of mobile, modular and relocatable units, delivering over 400,000 annual exams.
Efficiency gains, clinical effectiveness, and collaboration workflows
Alliance Medical has been a trusted partner to the NHS for 30 years, providing diagnostic imaging solutions to patients throughout the UK. This partnership with AGFA HealthCare will play a pivotal role in achieving the strategic vision for Alliance Medical's UK business to provide long-term, sustainable diagnostic imaging solutions on behalf of the NHS and other partners.
"The ground-breaking partnership between Alliance Medical and AGFA HealthCare will play a key role in enabling us to achieve our strategic vision, on behalf of our patients and stakeholders, and will support our commitment to integrating diagnostics into existing care pathways. AGFA HealthCare's solution really led from the front, and the digital ecosystem they brought together will deliver the experience, knowledge and innovation needed to create a complete cloud-based solution which covers the entire end-to-end patient pathway," says Pete Winchester, UK Managing Director at Alliance Medical.
"We are delighted to further strengthen our partnership with Alliance Medical Group and the relationship with Alliance Medical UK, which is an integral part of the health economy in the UK and beyond. Combining that bond with our close collaboration with our market-leading partners will enable us to jointly deliver a luminary solution that brings together each of our leading technologies: enterprise imaging, clinical decision support, complex workflow orchestration and advanced augmented intelligence. These will run through the heart of the solution to enable clinicians to deliver outcomes for patients and an exceptional user experience that is rich in efficiency gains," says Roberto Anello, Regional President for Northern Europe for AGFA HealthCare.
Transformative Technologies Delivering an Exceptional User Experience
- The solution includes the AGFA HealthCare Enterprise Imaging Platform, with Shared Workflow and the XERO® Exchange Network (XEN):
- Designed around scalability, connectivity and clinical collaboration, Enterprise Imaging enables near-real-time access to images and delivers powerful tools and features for diagnosis, collaboration, workflow and more. By facilitating "imaging without barriers," it supports patient and clinician work-life balance, as well as the balancing of radiologists' tasks and reporting workloads between different organisations.
- Fully embedded artificial intelligence and advanced visualisation tools for molecular imaging all support complex clinical workflows by providing a solution that is readily available regardless of location and time.
- The Enterprise Imaging Collaborator tool and the new Shared Workflow feature offer completely new ways of managing activity to match reporting capacity with demand, improve clinician collaboration through multi-author workflows, and align unified ‘specialist' Reporting Worklists with scarce reporting skills. The embedded XERO® application enables clinical teams to engage and share information. Enterprise Imaging is now entering the era of streaming clients capable of displaying large amounts of data in near real-time.
- AGFA HealthCare Enterprise Imaging is powered by Amazon Web Services (AWS) cloud services, which gives Alliance Medical access to the security, reliability and scalability of the public cloud.
The platform is complemented for referrals by two market-leading solutions, including:
- xWave Technologies' Smart Referring, an advanced portal for referring clinicians, integrated with Enterprise Imaging XERO®. xWave Smart Referring incorporates a dynamic Clinical Decision Support system which supports clinicians in accessing the most appropriate diagnostic test for their patients. Innovations such as the Smart Vetting workflow also reduce workloads for administrative and clinical staff, while improving patient safety and care.
- Streets Heaver's Compucare® PAS/EPR (patient administration system/electronic patient record): This market-leading solution is designed for private patient workflows as well as managing NHS contracts and eReferrals. It supports all clinical activity types from general clinic consultations to diagnostic imaging workflows, as well as other non-imaging diagnostic services. Patient engagement is supported through the Patient Portal.
About AGFA HealthCare
At AGFA HealthCare, we are transforming the delivery of care - supporting healthcare professionals across the globe with secure, effective, and sustainable imaging data management. As a company, we are dedicated to our customers, and we have harnessed a value framework of Mission, Vision, and Customer Delivery Principles into our routine operations. Through these principles, we commit a consistent high-yield code of conduct to our associates - channelling our experience and aspirations to all our stakeholders. Our Empowerer profile supports our focus on creating an exceptional experience through the power of technology and is an integral foundation of our company standards. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com and follow us on LinkedIn.
AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO® is a registered trademark of AGFA HealthCare N.V. All rights reserved. Compucare is a registered trademark of Streets Heaver Computer Systems Ltd. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.
Contact Information
Buse Kayar
buse.kayar@issuerdirect.com
SOURCE: AGFA HealthCare
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Sports Brand U.S. Polo Assn. Announced as Official Jersey and Apparel Sponsor for the Legendary Snow Polo World Cup St. Moritz13.1.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND ST. MORITZ, SWITZERLAND / ACCESS Newswire / January 13, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), will make its debut as the Official Jersey and Apparel Sponsor of the 41stSnow Polo World Cup St. Moritz, taking place January 23-25, 2026, on the iconic frozen lake of St. Moritz. U.S. Polo Assn.'s inaugural partnership with the world's most prestigious and legendary snow polo tournament underscores the brand's authentic ties to the game and its continued commitment to supporting polo around the world.Photo Caption: Snow Polo World Cup St. Moritz, with Official Jersey and Apparel Sponsor, U.S. Polo Assn. Photo Credit: Christian Sommer Snow Polo World Cup St. Moritz 2026 is already shaping up to be a record-breaking year, with unprecedented demand for tickets, elite international players, and global attention focused on one of the world's most high-profile polo tournaments played on snow. This event will see more
Clean Air Metals Announces 2026 Strategic Objectives in Historically Strong PGE and Copper Markets13.1.2026 01:10:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / January 12, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU0(OTCQB:CLRMF) is pleased to provide an overview of its 2026 objectives and highlights of 2025, for its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Critical Project Advancement Objectives Spot prices for platinum, copper and palladium have appreciated by 70% (1000 $/oz), 25% (1.20 $/lb) and 50% 624($/oz) respectively versus study prices, since the results of the Preliminary Economic Assessment (PEA) were announced in the October 9th release. Using the financial model published in the PEA and applying current spot metal prices (as of January 6th), the TBN project shows a $708M1 NPV8 and a pre-tax IRR of 100% (post-tax NPV8 = $494M1 and IRR = 84%).This is a significant improvement in the project outlook in comparison to the PEA results that featured a $219.4M2 pre-tax NPV8 and a pre-tax IRR of 39%. This year, cons
Germany Buys Eight MQ-9B SeaGuardian(R) RPA Through NSPA12.1.2026 20:00:00 CET | Press release
NSPA Supports NATO Countries in the Acquisition and Sustainment of GA-ASI's Advanced Multi-Domain RPA SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 12, 2026 / Germany's Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support and the NATO Support and Procurement Agency (NSPA) have announced the procurement of eight MQ-9B SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI). The program includes four Certifiable Ground Control Stations. First delivery is expected in 2028. Germany joins a growing list of NATO countries that have selected GA-ASI's advanced MQ-9B RPA for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in cold climates. SeaGuardian features two multi-mode surface-search radars that deliver wide-area maritime surveillance, with an option to add Anti-Submarine Warfare capa
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom